drugset / Trial / NCT03703427
Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.
Timeline
- Start
- 2018-11
- Primary completion
- 2023-11
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Vinorelbine | Small molecule | 60 mg/m2 | Oral |
Indications
No indication recorded.